Towards an understanding of psychedelic-induced neuroplasticity.
Abigail E. Calder, Gregor Hasler
Neuropsychopharmacology 2023 DOI: 10.1038/s41386-022-01389-z (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Review of preclinical and clinical studies |
| Topics | Neuroplasticity |
| Keywords | Psychedelics Mental health Neural connectivity |
| Citations | 303 |
| Key findings | Psychedelics promote neuroplasticity through mechanisms including dendritogenesis, synaptogenesis, neurogenesis, and expression of plasticity-related genes, particularly in the prefrontal cortex and hippocampus. |
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly, clinical improvements can last for months or years after treatment. It has been theorized that these long-term improvements arise because psychedelics rapidly and lastingly stimulate neuroplasticity. The focus of this review is on answering specific questions about the effects of psychedelics on neuroplasticity. Firstly, we review the evidence that psychedelics promote neuroplasticity and examine the cellular and molecular mechanisms behind the effects of different psychedelics on different aspects of neuroplasticity, including dendritogenesis, synaptogenesis, neurogenesis, and expression of plasticity-related genes (e.g., brain-derived neurotrophic factor and immediate early genes). We then examine where in the brain psychedelics promote neuroplasticity, particularly discussing the prefrontal cortex and hippocampus. We also examine what doses are required to produce this effect (e.g., hallucinogenic doses vs. "microdoses"), and how long purported changes in neuroplasticity last. Finally, we discuss the likely consequences of psychedelics' effects on neuroplasticity for both patients and healthy people, and we identify important research questions that would further scientific understanding of psychedelics' effects on neuroplasticity and its potential clinical applications.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Reviews evidence that psychedelics promote dendritogenesis, synaptogenesis, neurogenesis, and plasticity-related gene expression, particularly in prefrontal cortex and hippocampus, and discusses dose and duration questions.
Synthesized
Comparable studies
Other narrative reviews on neuroplasticity, most cited first.
Citations in the library
Cited by 251
- Canalization and plasticity in psychopathology Neuropharmacology December 27, 2022
- Treatment with psychedelics is psychotherapy: beyond reductionism The Lancet Psychiatry December 12, 2023
- Psychedelic therapy in the treatment of addiction: the past, present and future Frontiers in Psychiatry June 12, 2023
- Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial. Biological Psychiatry September 15, 2023
- Cardiovascular safety of psychedelic medicine: current status and future directions Pharmacological Reports October 24, 2023
and 246 more in the library
Cites 107
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
and 102 more in the library